TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

Grant

Date/time Interval

  • August 8, 2019 - August 7, 2024
  • Total Award Amount

  • 159300.00
  • Direct Costs

  • 122538.00
  • Sponsor Award Id

  • Contributor

  • Rocque M.D., Gabrielle   Investigator  
  • Stringer-Reasor M.D., Erica   Principal Investigator  
  • Yang M.D., Ph.D., Eddy   Investigator